CD247 and neoplasm: Similarly, Lei et al. demonstrated that combining anti-CD47 monoclonal antibodies with dual CD3ζ–TIR CAR macrophages resulted in superior tumor eradication in HEPG2 cells in vivo (Lei et al., 2024).